Recapitulating sinister Cold War practices that informed American
ruling class consensus when it came to secretly toying with nature's
most deadly pathogens, (a) because they
,
the profound failure by the administration to rein-in out-of-control
corporate grifters, militarists and scientists thirsting after an
endless flow of taxpayer dollars, have put us all on a potential glide
path towards the abyss.
Since the roll-out of the Obama
product-line January 21, on issues ranging from war and peace to
economic justice and from civil liberties to healthcare, the "change"
team exhibit the same callous disregard for disarmament proposals that
characterized their Bushist predecessors in the Oval Office.
Nowhere
is this reality so transparently delineated than by the
administration's continuing efforts to derail plans to revitalize the
moribund Biological Weapons Convention (
), rejecting binding verification protocols that would finally give the 1972 treaty teeth.
From
her perch as U.S. Undersecretary of State for Arms Control and
International Security, Ellen Tauscher, a former Democratic
congresswoman from the San Francisco Bay Area (in other words, a
feckless "liberal" who spent her career paying lip-service to the
antiwar sentiments of her constituents--and then voting in favor of
every blood-soaked imperialist adventure undertaken by the Bush regime)
rejected international monitoring of military and pharmaceutical sites
that might employ research for illicit purposes, e.g., the fabrication
of banned biological weapons.
"The Obama administration will not seek to revive negotiations on a verification protocol to the convention," Tauscher
delegates December 9 at the annual meeting of the States Parties to the Biological Weapons Convention in Geneva.
The
position outlined last week by the administration eerily follows in the
footsteps of the previous government. In 2001, there was broad support
internationally for revitalizing the BWC draft Protocol; a long,
circuitous process undertaken back in 1991.
But during these earlier negotiations, the U.S. Pharmaceutical Research and Manufacturers of America (
)
released a position paper opposing the routine inspection of
laboratories and other research facilities on the grounds of
safeguarding "confidential business information," a position they have
reiterated today.
This, along with U.S. Defense
Department opposition killed the deal after the American delegation,
under instructions from arch neocon John Bolton who then held
Tauscher's brief, argued that an international inspections regime would
put U.S. "national security" at "risk" by allowing spot checks of
suspected U.S. weapons sites.
Revealing a warmer and fuzzier,
though no less obstructionist side than blustery Bolton, the
Undersecretary mounted a charm offensive in Geneva, touting the
National Security Council's (
NSC)
"National Strategy for Countering Biological Threats" as a major
transformation of the U.S. position. It wasn't. Tauscher told
delegates: "The United States intends to implement this [NSC] strategy
through renewed cooperation and more thorough consultations with our
international counterparts in order to prevent the misuse and abuse of
science while working together to strengthen health security around the
world."
However, not a
single
word in the 23-page NSC document addresses the vital issue of
verification. Indeed, while no-holds-barred inspections of nuclear
weapons' facilities undergird international treaties governing the
destruction of warheads and missiles, thus ensuring compliance with
treaty obligations by states, when it comes to biological weapons the
"National Strategy" skirts the question entirely. Why?
While the
United States claims that it will "advance policies and practices that
establish and reinforce norms against the misuse of the knowledge and
capabilities that arise from the life sciences while encouraging their
free and open availability for peaceful and beneficial use," a call to
"develop and employ complementary and multi-layered systems for
influencing, identifying, inhibiting, and interdicting biological
threats" does nothing to constrain state or corporate actors from
exploiting the life sciences for nefarious ends, to wit, work with dual
use select agents that can be diverted into surreptitious weapons'
programs.
This is crucial. While the document asserts that
America's "relationships with the United Nations, international
organizations, foreign governments, and the private sector are critical
to the success of our efforts" the fact is, the "private sector" and
the secret state's own Defense Department are dead-set against any
initiative that give international arms' control monitors access to
their facilities.
Claiming that the United States "has carefully
reviewed previous efforts to develop a verification protocol," the
administration has "determined that a legally binding protocol would
not achieve meaningful verification or greater security."
Echoing Tauscher and the NSC's lame reasoning, Barry Kellman, president of the
International Security and Biopolicy Institute told
The Hill
he "agreed," and told the publication "that given the rapid evolution
of the biological market, technologies that once could only be made in
a laboratory can now be made anywhere, so it would be impossible to
verify that a country is holding true to the convention protocols."
Really? Perhaps then, Mr. Kellman would care to enlighten us as to
which select agent was used in the first and to date, only, bioterrorist attack of the 21st century, and
where pray tell it might have come from.
Editing Out the Secret State: The 2001 Anthrax AttacksAs has generally been accepted by scientific experts and as
The Baltimore Sun revealed
back in 2001, "for nearly a decade, U.S. Army scientists at Dugway
Proving Ground in Utah have made small quantities of weapons-grade
anthrax that is virtually identical to the powdery spores used in the
[October 2001] mail attacks."
Investigative journalist Scott
Shane disclosed that Dugway's Life Sciences Division "made hundreds of
kilograms of anthrax for bombs designed to kill enemy troops over
hundreds of square miles" during the Cold War.
Indeed, the
"extraordinary concentration" of the finely-milled powdered anthrax
mailed to the media and members of Congress was "in the range of 1
trillion spores per gram" which "meant that the letter could have
contained 200 million times the average dose necessary to kill a
person."
Researchers at Northern Arizona University determined
that "the genetic fingerprint of the mailed anthrax is
indistinguishable from that of the Ames 'reference strain,' which is
the strain used most often at Fort Detrick and Dugway, according to a
scientist familiar with the genetic work," the
Sun reported.
Years
later, former Ft. Detrick deputy commander Richard Spertzel told
investigative journalists Bob Coen and Eric Nadler that "the material
that was in the Daschle/Leahy letter was "1.5 to 3 microns in particle
size" and characterized the refinement "as super sophisticated ...
phenomenal." When investigators attempted to examine samples under a
microscope, "it readily floated off the slides."
In other words,
the "genetic fingerprint" and "extraordinary concentration" of the
weaponized anthrax used in the attack would require a
team of individuals, and
not
a proverbial "lone nut" to produce a biotoxin possessing such
exquisitely lethal characteristics. The inescapable conclusion is that
the anthrax used to murder five people, sicken dozens of others and
terrorize the rest of us, could only have come from a
state program or one operating under contract to a government agency.
Could
the deadly biotoxin have been diverted from a U.S. defense facility or
corporate lab by a group of "black box" scientists operating under the
radar for their own nefarious ends, i.e. strengthening the state's
repressive hand within the social-political context of the 9/11
attacks? It is certainly possible and cannot be ruled out.
As I previously reported,
Global Security Newswire (GSN) disclosed
in June that "a recently completed inventory at a major U.S. Army
biodefense facility found nearly 10,000 more vials of potentially
lethal pathogens than were known to be stored at the [Ft. Detrick]
site."
According to reporter Martin Matishak, the 9,220 samples
discovered "included the bacterial agents that cause plague, anthrax
and tularemia; Venezuelan, Eastern and Western equine encephalitis
viruses; Rift valley fever virus; Junin virus; Ebola virus; and
botulinum neurotoxins."
While Ft. Detrick's deputy commander
Col. Mark Kortepeter claimed there are "multiple layers of security"
and that "a lot of buffers [would] prevent anyone who shouldn't be in
the laboratory from getting in in the first place and then preventing
them taking something out with them," this dodges the question of
whether someone who
was authorized to be inside
Ft. Detrick or any of the other 400 U.S. facilities that have Biosafety
Level-3 or Biosafety Level-4 laboratories,
could smuggle out deadly toxic substances.
The New York Times reported
December 9, that Tauscher rejects a strict regulatory regimen that
would monitor state bioweapons research and development because of the
"regulatory burdens that verification would place on the American
pharmaceutical industry and on the military's bio-defense research
activities."
Given the available facts surrounding the 2001
anthrax terrorist incident and the FBI's subsequent cover-up,
Tauscher's fear of "regulatory burdens" on the "pharmaceutical
industry" and the state's own "bio-defense research activities" are
certainly misplaced and should be viewed with suspicion.
Big Pharma and Congress: Best Friends Forever!While
journalists and researchers have explored ethically-challenged
relationships amongst former Defense Department officials and the
weapons' industry, most recently by
USA Today, and have described the oft-cited revolving door as
entrée
to an exclusive and highly lucrative good 'ol boys club; call it a
Beltway version of a retirement village for Pentagon clock-punchers.
Inquiring
minds can't help but wonder: does the same clubby atmosphere pervade,
and inform, the policy decisions made by denizens of the
Bioweapons-Industrial-Complex? Let's take a look!
Take the
Alliance for Biosecurity, a Big Pharma lobby shop aligned with the
Center for Biosecurity of the University of Pittsburgh Medical Center (
UPMC),
as a starting point. Self-described as "a collaboration among the
Center for Biosecurity and 13 pharmaceutical and biotechnology
companies," one "whose mission is to work in the public interest to
improve prevention and treatment of severe infectious
diseases--particularly those diseases that present global security
challenges," one discovers that similar relationships between academia,
industry and government abound.
Since
Antifascist Calling first
reported
on Alliance efforts to increase state funding of biotechnology and
"biodefense" research in August, all references to the Alliance for
Biosecurity have been scrubbed from UPMC's web site. Indeed, all traces
of the lobby shop's activities, including group policy statements and
testimony before relevant congressional committees have simply vanished.
But
why, pray tell, would they take evasive action in the first place? And
more importantly, what do they have to hide? As it turns out, quite a
lot.
According to
The Washington Times,
when the Center for Biosecurity's director, Dr. Tara O'Toole, was
nominated for her current post as Undersecretary of Science and
Technology at the Department of Homeland Security, she had "served as a
key adviser for a lobbying group funded by the pharmaceutical industry
that has asked the government to spend more money for anthrax vaccines
and biodefense research."
Reporter Tim McElhatton disclosed that
O'Toole "never reported her involvement with the lobbying group called
the Alliance for Biosecurity in a recent government ethics filing."
The Washington Times
further reported that the Alliance "has spent more than $500,000
lobbying Congress and federal agencies--including Homeland
Security--since 2005, congressional records show."
"In written
testimony to Congress" according to McElhatton, "Dr. O'Toole said the
alliance was 'created to protect the Center for Biosecurity's status as
an honest broker between the biopharma companies and the U.S.
government'." As is well known, $500,000 buys much in the way of
"honesty" in the halls of Congress!
In an October 31 letter to
House Speaker Nancy Pelosi (D-CA) "signed by Dr. O'Toole and two other
alliance officials, the group called on Congress to include more than
$900 million for the 'advanced development of medical countermeasures'
to be administered by the Biomedical Advanced Research and Development
Authority."
The Washington Times
revealed that the letter was also "signed by the chief executive
officer of member company PharmAthene, David Wright, who was one of the
two first co-chairmen for the alliance after its creation in 2005."
McElhatton
reported that according to a Securities and Exchange Commission filing
"Mr. Wright's company has a big financial interest in securing work
from the authority," and that "PharmAthene has been trying to win a
contract administered by the authority to supply 25 million doses of an
anthrax vaccine to the national stockpile."
According to a
press release,
the firm announced that PharmAthene "will participate in and present
data at the HHS Public Health Emergency Medical Countermeasures
Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in
Washington, DC Dec. 2-4, 2009."
Indeed, the PHEMCE work shop
"will bring together public and private sector stakeholders for a
dynamic dialogue on the current state of medical countermeasure
preparedness, PHEMCE initiatives in the past year, and plans for moving
forward to enhance national capabilities to respond to a public health
emergency."
When "moving forward" entails the expenditure of
nearly one billion dollars for "countermeasure preparedness," one can
be sure that companies on the make will be all ears!
Former
Bushist Secretary of Health and Human Services, Tommy Thompson, averred
that the PHEMCE workshop "is very timely given the WMD Commission's
conclusion that terrorists are much more likely to attack America with
a biological weapon than a nuclear weapon."
Despite the fact
that weapons' experts have not reached a consensus on the Commission's
alarmist report, given the extreme difficulty faced by "terrorists" to
fabricate biotoxins into an effective weapon, Thompson claims, "now
that our national experts have made this warning clear, we need to take
the immediate steps necessary to protect against potential biological
attacks against the U.S. homeland. In particular, we need to move
forward efforts to build and stockpile appropriate biological
countermeasures, such as next-generation anthrax vaccines, recombinant
influenza vaccines, and novel antivirals."
Among the "experts"
consulted by the WMD Commission were none other than Dr. O'Toole's
Center for Biosecurity who have called for the expenditure of some $3.4
billion annually on "countermeasure development to reach 90 percent
chance of success defending the country against bioterrorism threats."
Nowhere
however, in the PharmAthene press release is it disclosed that the
former HHS Secretary has a proprietary interest in securing federal
dollars allegedly to "enhance national capabilities" to better respond
"to a public health emergency." Currently, Thompson is the President of
Logistics Health, Inc., a firm that does extensive business with the
U.S. Department of Defense for what it euphemistically calls "military
readiness."
Craig Holman, the legislative director of the
watchdog group Public Citizen, said that O'Toole's lack of transparency
"definitely and clearly runs counter to the intent of the law."
What
was the response by Senate Democrats, quick to denounce the "culture of
corruption" of their coconspirators across the aisle? According to
The New York Times,
Senate Majority Leader Harry Reid "slammed Republicans for slowing
down, and in some cases, blocking the confirmation of nominees for
various posts in the Obama administration."
Neither Reid, nor for that matter the
Times,
breathed a word about O'Toole's obvious conflict of interest and cosy
relationships with biodefense firms she would presumably oversee from
her perch at DHS.
Instead, we are lavished with empty rhetoric from Reid who told the
Times:
"'For that position, [DHS Undersecretary] President Obama nominated an
expert in combating both pandemics and bioterror attacks,' Mr. Reid
said, adding: 'Imagine that: Americans are bracing against a flu
epidemic here at home and threats of terrorism from abroad, the
President nominated someone highly experienced in both of those areas,
and Republicans are saying no'."
Despite revelations of serious ethical breaches, O'Toole was confirmed by the Senate November 4.
The Ties that Bind (And Pay Handsomely!)The
close proximity of O'Toole, the Center for Biosecurity and now, the
Department of Homeland Security to Alliance members such as Bavarian
Nordic; Cangene Corporation; DOR BioPharma, Inc.; DynPort Vaccine
Company LLC; Elusys Therapeutics, Inc.; Emergent BioSolutions;
Hematech, Inc.; Human Genome Sciences, Inc.; NanoViricides, Inc.;
Pfizer Inc.; PharmAthene; Siga Technologies, Inc.; Unither Virology
LLC, , as well as associate Alliance member, the spooky, CIA-connected
Battelle Memorial Institute, might just help explain the Obama
administration's opposition to strengthening the BWC.
According to the Center for Responsive Politic's OpenSecrets.org
database,
the Alliance for Biosecurity have contributed some $600,000 to
congressional grifters since 2005 through the Philadelphia law firm
Drinker, Biddle & Reath.
While chump change when it comes to assuring that the best congresspeople money can buy stay "on-message," OpenSecrets
reports
that since 1990, Big Pharma and their allies in the health products
industry have spent a whopping $177,030,005 on "influence and
lobbying." Breaking down the numbers, the watchdog group avers that the
bulk of contributions have benefited Republicans ($111,405,078 or 63%)
vs. Democrats ($65,056,643 or 37%).
In
The Washington Times
piece cited above, ethics groups have said that the Alliance's set-up
"is an example of what critics call "stealth lobbying," in which
like-minded companies form a loosely knit compact and spend lots of
money lobbying the government. The arrangement is legal, but it exposes
loopholes that prevent the public from finding out how much money each
company pays and whether one business exerts more control over the
others."
Alliance legal counsel Anita Cicero told the paper,
"the group is complying with all applicable federal laws" and that the
group "does not generate income, does not have a bank account and does
not owe taxes." She told the paper the organization "was formed so
companies, academic institutions and the government" could work
together to "accelerate the development of therapeutic and vaccine
countermeasures."
"Countermeasures" that markedly add to the corporatist bottom line.
As
Antifascist Calling previously
reported, the National Biodefense Science Board (NBSB), chock-a-block with industry insiders and academic shills, posted an August 11
notice buried in the Federal Register.
Rescued from oblivion by the whistleblowing intelligence and security web site
Cryptome, we were informed that NBSB's "Market & Sustainability Work Group" seek to hand over even more cash to industry partners.
Seeking
public comment on the group's working document, "Inventory of Issues
Constraining or Enabling Industry Involvement in Medical Countermeasure
Efforts," NBSB is seeking to further "streamline" the Food and Drug
Administration's already lax review process in a move meant to further
"incentivize" industry by "increased federal funding for advanced
development, in the form of cost-reimbursement contracts and rewarding
private-capital investments with milestone payments at procurement."
Under
NBSB's proposal, the drug industry stands to grab "reimbursement of
development costs + 15%, with return-on-working-capital at 22%, and
cost-of-money-for-capital at 15%."
If said corporate patriots
swing into action during a national emergency, then "compensation if
commercial product(s) during emergencies (e.g., lost sales, market
share, delayed licensing" are fully paid by the federal government.
Talk about a robust "public-private partnership" in action!
But wait, there's more!GSN
reported in October that Alliance member
Human Genome Sciences Inc.
had earned $160 million from the federal government for sales of its
ABthrax vaccine, despite a Food and Drug Administration report that
stated although the product performed better than a placebo (!) "it is
still unknown how well these models and results predict efficacy in
humans." Despite these equivocal findings, "Washington has placed an
order for 65,000 doses of ABthrax for the country's emergency medicines
reserve."
Now that's what I call a streamlined review process!
Earlier in October,
GSN disclosed that Alliance member
Emergent BioSolutions
won $4.9 million in funding from the U.S. National Institute of Allergy
and Infectious Diseases, a branch of the National Institutes of Health,
"for the development of a new anthrax vaccine that could require only
two doses to provide protection."
As investigative journalists and filmmakers Bob Coen and Eric Nadler revealed in
Anthrax War and a companion book,
Dead Silence: Fear and Terror on the Anthrax Trail, Emergent BioSolutions has a
very interesting pedigree indeed.
When
the State of Michigan auctioned off the Michigan Biological Products
Institute (MBPI) in 1998, standing in the wings with a check for $24
million were Lebanese financiers Ibrahim El-Hibri and son Fuad, "an
international telecom magnate" according to Coen and Nadler. During
this period, the firm the El-Hibri's had founded after scooping-up MBPI
for a song, BioPort, "held the exclusive contract to provide the U.S.
government with the anthrax vaccine, and that in addition to the
physical plant, the Michigan sale included $130 million in contracts
with the Department of Defense."
During their investigation,
Coen and Nadler learned "that the El-Hibris had participated in the
privatization of portions of the United Kingdom's leading biodefense
facility, Porton Down, a decade earlier" and that "with the acquisition
of the Michigan plant, the family had planted stakes in the only two
leading anthrax vaccine producers in the West." What makes this
particularly troubling according to Coen and Nadler, is the fact that
the "El-Hibri's did not have science backgrounds or biotech business
experience before the Porton takeover--but were clearly canny
investors."
Alarmingly, "the troubling fact [was] that the sale
of MBPI to BioPort had transferred control of a sensitive government
program to a network of companies, one of which was headquartered in
the Dutch Caribbean."
Indeed, "Fuad El-Hibri himself informed
Congress in 1999 that the controlling shareholder in BioPort--Intervac
LLC--was partly owned by I and F Holdings NV, a Netherlands Antilles
investment company owned by his father."
None of this troubled
Congress in the least since, as Coen and Nadler relate "no one on the
House Committee on Government Reform asked him if El-Hibri senior had
any partners in I and F Holdings." These disturbing facts led the
investigative journalists to wonder: "Who actually owned the largest
anthrax vaccine manufacturing plant in the West, if not the world? Who
really knew."
Fast forward a decade and according to
GSN
BioPort, now Emergent BioSolutions, "is the producer of BioThrax, the
only vaccine licensed by the Food and Drug Administration for the
prevention of anthrax disease. The company is also developing other
anthrax treatments and countermeasures against diseases such as
botulism and hepatitis B." Funds for developing the vaccine were
provided "through the American Recovery and Reinvestment Act of 2009."
Last month,
GSN revealed that Alliance member, Danish firm
Bavarian Nordic
will receive some $40 million for a freeze-dried version of the firm's
Imvamune vaccine for smallpox. GSN reported that "Bavarian Nordic has
received $680 million in contracts for Imvamune from the U.S.
government. Washington has ordered 20 million doses of the vaccine in
its liquid-frozen form and has the option of buying another 60
million," according to a company
press release.
This, despite the fact that smallpox has disappeared as an international public health threat. However as the
Sunshine Project's Edward Hammond revealed in
Emerging Technologies: Genetic Engineering and Biological Weapons,
when a U.S. research team at the State University of New York in Stony
Brook synthesized poliovirus "from scratch," the responsible
bioresearch community were alarmed.
Hammond commented that "the
experiment exemplifies possibilities that generate real problems if
similar techniques become applicable to agents such as smallpox. Today
it is unlikely (though not completely impossible) that countries apart
from Russia and the USA have access to smallpox virus. This is the
basis of the current threat assessments with regard to smallpox, which
rate the likelihood of a smallpox attack very low. Should it become
possible in a few years to build smallpox virus in the laboratory, the
situation would be turned upside down. The relative security that can
be assumed today (at least for most countries in the world) will
evaporate."
Since Hammond's piece first appeared in 2003, is it
plausible that synthetic smallpox could have been ginned-up in a top
secret U.S. research facility, hence contingency planning by secret
state officials to have a freeze-dried, hence longer-lived vaccine on
hand? We don't know.
Examining only the three above-named firms, OpenSecrets reports that since 2000,
Human Genome Sciences has expended some $24 million since 2002 for lobbying;
Emergent BioSolutions has spent some $10.9 on lobbying efforts since 2003, and
Bavarian Nordic has spent some $21.7 lobbying Congress since 2002.
Given the enormous outlay of taxpayer largesse to firms that have profited handily under the
Project BioShield Act of 2004, a grotesque piece of Bushist legislative flotsam, and the nearly $60 billion dollars reported by the
Center for Arms Control and Non-Proliferation
spent on so-called biodefense by the federal government, one can only
conclude that lobbying activities by Big Pharma is an investment
well-spent!
Keep in mind too, that the expenditure of federal dollars for Project BioShield and related programs
do not
include black budget allocations concealed by the CIA and Pentagon
under a welter of above top secret Special Access Programs, a subject
that
Antifascist Calling will explore in future reports.
ConclusionAs
the Sunshine Project's Edward Hammond has warned: "Rapid developments
in biotechnology, genetics and genomics pose a variety of
environmental, ethical, political, and social questions. And because
they open up tremendous new possibilities for biological warfare, these
technological developments have grave implications for peace and
security."
We must view the Obama administration's cynical
opposition to strengthening the Biological Weapons Convention because
of the "regulatory burdens that verification would place on the
American pharmaceutical industry and on the military's bio-defense
research activities" as a dire international public health emergency,
one which University of Illinois constitutional law professor Francis
Boyle, the author of the 1989 Bioweapons Anti-Terrorism Act, has called
"a catastrophe waiting to happen."
We proceed blindly along this path at our own peril.
Tom Burghardt is a researcher and activist based in the San Francisco Bay Area. In addition to publishing in Covert Action Quarterly and Global Research,
an independent research and media group of writers, scholars,
journalists and activists based in Montreal, his articles can be read
on Dissident Voice, The Intelligence Daily, Pacific Free Press , Uncommon Thought Journal, CJO's Avenger212, and the whistleblowing website Wikileaks. He is the editor of Police State America: U.S. Military "Civil Disturbance" Planning, distributed by AK Press.
Recent Comments